July 12, 2011
In this eleventh episode of "This Week in Pediatric Oncology" hosts Dr. Tim Cripe and Dr. Lars Wagner discuss with guest Dr. Brian Weiss (Cincinnati Children's Hospital) the implications of the recent results comparing two chemotherapy combinations for transplant regimens in children with high-risk neuroblastoma in Europe. The BuMel (busulfan, melphalan) regimen resulted in better survival and lower toxicity than CEM (carboplatin, etoposide, melphalan), a regimen used for transplant in the COG for a decade.
This SIOP trial was one of the plenary presentations at ASCO in June 2011. In this lively and informative discussion, Dr. Brian Weiss explains the COG response to these results due to the difference in induction regimens. The BuMel regimen will be used in the upcoming MIBG frontline pilot that Dr. Weiss is leading as principal investigator.
Dr. Weiss and TWiPO hosts also discussed the recent paper Safety and efficacy of tandem (131) I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma authored by Johnson et al in Pediatr Blood Cancer. 2011 Apr 14
Please send questions and comments to email@example.com